Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wood Group extends Sidara 'put up or shut up' deadline

(Sharecast News) - Wood Group said on Monday that the deadline by which Dubai's Sidara must either announce a formal intention to make an offer for the company or walk away has been extended. Under UK takeover rules, Sidara had until 24 March but this has now been pushed back to 17 April, at the request of Wood Group.

The oilfield services and engineering company confirmed on 24 February that it had received a non-binding, conditional proposal from Sidara about a potential cash offer.

"Following this, Wood provided Sidara with access to due diligence information and entered into discussions with Sidara," it said on Monday.

Wood said discussions are continuing and the board of Wood has therefore requested an extension to the 'put up or shut up' deadline.

The company said a further announcement will be made in due course, adding that there can no certainty that an offer will be made, nor as to the terms on which it will be made.

At 0935 GMT, the shares were up 2% at 39.16p.

Russ Mould, investment director at AJ Bell, said: "Investors continue to keep their fingers crossed that Wood Group will be acquired for a premium.

"The bearer of much bad news in recent months, Wood Group's share price has been like a slinky slowly dropping down the stairs.

"That hasn't stopped certain opportunistic investors from betting on the company being taken private at a higher price than its shares currently trade."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.